Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone.

Yendewa GA, Sahr F, Lakoh S, Ruiz M, Patiño L, Tabernilla A, Deen GF, Sesay M, Salata RA, Poveda E.

J Antimicrob Chemother. 2019 Jul 1;74(7):2024-2029. doi: 10.1093/jac/dkz134.

2.

Seroprevalence of Hepatitis B, Hepatitis C, and Human T-Cell Lymphotropic Virus Infections in HIV-Infected Patients in Sierra Leone.

Yendewa GA, Sahr F, Aguilera A, Lakoh S, Sesay M, Deen GF, Patiño L, Poveda E, Salata RA.

Am J Trop Med Hyg. 2019 Jun;100(6):1521-1524. doi: 10.4269/ajtmh.18-1001.

PMID:
30938283
3.

Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice.

Alvarez M, Casas P, de Salazar A, Chueca N, Guerrero-Beltran C, Rodríguez C, Imaz A, Espinosa N, García-Bujalance S, Pérez-Elías MJ, García-Alvarez M, Iribarren JA, Santos J, Dalmau D, Aguilera A, Vinuesa D, Gutiérrez F, Piérola B, Molina JM, Peraire J, Portilla I, Gómez-Sirvent JL, Olalla J, Galera C, Blanco JR, Riera M, García-Fraile L, Navarro G, Curran A, Poveda E, García F; CoRIS .

J Antimicrob Chemother. 2019 Jun 1;74(6):1693-1700. doi: 10.1093/jac/dkz067.

PMID:
30838386
4.

Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines.

Cid-Silva P, Margusino-Framiñán L, Balboa-Barreiro V, Pernas-Souto B, Mena-De-Cea Á, Martín-Herranz I, Castro-Iglesias Á, Poveda E.

J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958218821940. doi: 10.1177/2325958218821940.

PMID:
30798655
5.

Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.

Cid-Silva P, Fernández-Bargiela N, Margusino-Framiñán L, Balboa-Barreiro V, Mena-De-Cea Á, López-Calvo S, Vázquez-Rodríguez P, Martín-Herranz I, Míguez-Rey E, Poveda E, Castro-Iglesias Á.

Basic Clin Pharmacol Toxicol. 2019 Apr;124(4):479-490. doi: 10.1111/bcpt.13161. Epub 2018 Dec 7.

PMID:
30388308
6.

High Prevalence of Late-Stage Disease in Newly Diagnosed Human Immunodeficiency Virus Patients in Sierra Leone.

Yendewa GA, Poveda E, Lakoh S, Yendewa SA, Jiba DF, Salgado-Barreira A, Sahr F, Salata RA.

Open Forum Infect Dis. 2018 Aug 23;5(9):ofy208. doi: 10.1093/ofid/ofy208. eCollection 2018 Sep.

7.

HIV/AIDS in Sierra Leone: Characterizing the Hidden Epidemic.

Yendewa GA, Poveda E, Yendewa SA, Sahr F, Quiñones-Mateu ME, Salata RA.

AIDS Rev. 2018 Apr-Jun;20(2):104-113. Review.

PMID:
29938704
9.

Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies.

Grandal M, Pernas B, Tabernilla A, Mariño A, Álvarez H, Valcarce N, Mena A, Castro-Iglesias A, Pérez AB, Delgado M, Poveda E.

J Med Virol. 2018 Jun;90(6):1094-1098. doi: 10.1002/jmv.25048. Epub 2018 Mar 12.

PMID:
29427437
10.

Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors.

Cid-Silva P, Margusino-Framiñán L, Balboa-Barreiro V, Martín-Herranz I, Castro-Iglesias Á, Pernas-Souto B, Llibre JM, Poveda E.

AIDS. 2018 Jan 2;32(1):121-125. doi: 10.1097/QAD.0000000000001679.

PMID:
29112068
11.
12.

Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: potential role as a biomarker of HIV replication.

Pernas B, Rego-Pérez I, Tabernilla A, Balboa V, Relaño S, Grandal M, Crespo M, Mena Á, Castro-Iglesias Á, Blanco FJ, Poveda E.

J Antimicrob Chemother. 2017 Nov 1;72(11):3159-3162. doi: 10.1093/jac/dkx272.

PMID:
28961892
13.

Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance.

Cid-Silva P, Llibre JM, Fernández-Bargiela N, Margusino-Framiñán L, Balboa-Barreiro V, Pernas-Souto B, Martín-Herranz I, Castro-Iglesias Á, Poveda E.

Basic Clin Pharmacol Toxicol. 2017 Nov;121(5):442-446. doi: 10.1111/bcpt.12828. Epub 2017 Jul 16.

14.

Minimizing Next-Generation Sequencing Errors for HIV Drug Resistance Testing.

Fernández-Caballero JA, Chueca N, Poveda E, García F.

AIDS Rev. 2017 Oct-Dec;19(4):231-238. Review.

PMID:
28534892
15.

When is Early Antiretroviral Therapy Early Enough for HIV Remission?

Poveda E, Crespo M.

AIDS Rev. 2017 Apr - Jun;19(2):113-114. Review.

PMID:
28534887
16.

Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected.

Meijide H, Pértega S, Rodríguez-Osorio I, Castro-Iglesias Á, Baliñas J, Rodríguez-Martínez G, Mena Á, Poveda E.

AIDS. 2017 May 15;31(8):1099-1107. doi: 10.1097/QAD.0000000000001448.

PMID:
28441174
17.

Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.

Tabernilla A, Grandal M, Pernas B, Castro-Iglesias A, Rodríguez-Osorio I, Mena A, Delgado M, Cid P, Pedreira JD, Poveda E.

Eur J Gastroenterol Hepatol. 2017 Jul;29(7):781-785. doi: 10.1097/MEG.0000000000000882.

PMID:
28410351
18.

HTLV infection in HCV-antibody positive patients in Spain.

Treviño A, Aguilera A, Rodríguez-Iglesias MA, Hernandez A, Benito R, Roc L, Ramos JM, Ortíz de Lejarazu R, Poveda E, Rodríguez C, Del Romero J, Calderon E, García J, Requena S, Soriano V, de Mendoza C.

AIDS Res Hum Retroviruses. 2017 Ocy;33(10):1013-1017. doi: 10.1089/AID.2016.0323. Epub 2017 Mar 7.

PMID:
28269998
19.

Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV.

Mena A, Meijide H, Rodríguez-Osorio I, Castro A, Poveda E.

HIV Med. 2017 Oct;18(9):685-689. doi: 10.1111/hiv.12502. Epub 2017 Feb 23.

PMID:
28230318
20.

Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients.

Rodríguez-Osorio I, Cid P, Morano L, Castro Á, Suárez M, Delgado M, Margusino L, Meijide H, Pernas B, Tabernilla A, Pedreira JD, Mena Á, Poveda E.

J Clin Virol. 2017 Mar;88:58-61. doi: 10.1016/j.jcv.2017.01.003. Epub 2017 Jan 18.

PMID:
28183063
21.
22.

News on Viral Hepatitis in HIV: Update from the 2016 GEHEP Conference.

Poveda E, Puoti M, García-Deltoro M, Pineda JA, Téllez F, Granados R, Morano L, García F.

AIDS Rev. 2017 Jan-Mar;19(1):47-53. Review.

PMID:
28182613
23.

Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure.

Grandal M, Pernas B, Mariño A, Álvarez H, Tabernilla A, Castro-Iglesias Á, Mena Á, Delgado M, Pértega S, Poveda E.

J Med Virol. 2017 Jul;89(7):1304-1308. doi: 10.1002/jmv.24766. Epub 2017 Mar 14.

PMID:
28079256
24.

Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.

Poveda E, Hernández-Quero J, Pérez-Elías MJ, Ribas MA, Martínez-Madrid OJ, Flores J, Navarro J, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestaran A, García F, Paredes R; PROTEST study group.

HIV Med. 2017 Aug;18(7):482-489. doi: 10.1111/hiv.12479. Epub 2016 Dec 30.

25.

Cancer Incidence in Persons Living With HIV.

Meijide H, Mena Á, Rodríguez-Osorio I, Castro-Iglesias Á, Poveda E.

Clin Infect Dis. 2017 Feb 1;64(3):388-389. doi: 10.1093/cid/ciw759. Epub 2016 Nov 14. No abstract available.

PMID:
28013260
26.

New Strategies for a Comprehensive Fight Against HIV Infection using Monoclonal Antibody Therapy.

Poveda E, Crespo M.

AIDS Rev. 2016 Jul - Sep;18(3):166. Review.

PMID:
27721508
27.

Trends in hospital admissions, re-admissions, and in-hospital mortality among HIV-infected patients between 1993 and 2013: Impact of hepatitis C co-infection.

Meijide H, Mena Á, Rodríguez-Osorio I, Pértega S, Castro-Iglesias Á, Rodríguez-Martínez G, Pedreira J, Poveda E.

Enferm Infecc Microbiol Clin. 2017 Jan;35(1):20-26. doi: 10.1016/j.eimc.2016.07.012. Epub 2016 Sep 5.

PMID:
27609631
28.

Brief Report: European Mitochondrial Haplogroups Impact on Liver Fibrosis Progression Among HCV and HIV/HCV-Coinfected Patients From Northwest Spain.

Tabernilla A, Rego-Pérez I, Grandal M, Pernas B, Pértega S, Delgado M, Mariño A, Álvarez H, Mena A, Rodríguez-Osorio I, Pedreira JD, Blanco FJ, Poveda E.

J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):149-53. doi: 10.1097/QAI.0000000000001097.

PMID:
27258234
29.

Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain.

Pernas B, Grandal M, Tabernilla A, Cid P, Pértega S, Castro-Iglesias Á, Mena Á, Margusino L, Pedreira JD, Poveda E.

J Med Virol. 2016 Dec;88(12):2125-2131. doi: 10.1002/jmv.24585. Epub 2016 Jun 6.

PMID:
27218208
30.
31.

Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?

Pernas B, Grandal M, Pertega S, Cañizares A, Castro-Iglesias Á, Mena Á, Rodriguez-Osorio I, Tabernilla A, Pedreira JD, Poveda E.

J Antimicrob Chemother. 2016 Apr;71(4):1051-5. doi: 10.1093/jac/dkv433. Epub 2015 Dec 24.

PMID:
26702924
32.
33.

News on HIV-HCV Coinfection: Update From the 2015 GEHEP Conference.

Poveda E, Wyles D, Morano L, Pineda JA, García F; GEHEP.

AIDS Rev. 2015 Oct-Dec;17(4):231-7. Review.

PMID:
26616846
34.

Lung cancer in patients living with HIV infection.

Meijide H, Mena A, Marcos PJ, Rodriguez-Osorio I, Suárez-Fuentetaja R, Castro A, Poveda E, Pedreira JD.

AIDS. 2015 Nov;29(17):2363-4. doi: 10.1097/QAD.0000000000000840. No abstract available.

PMID:
26544707
35.

The START Trial: Definitive Evidence to Treat All HIV-Positive Persons Regardless of CD4 Counts.

Tabernilla A, Poveda E.

AIDS Rev. 2015 Jul-Sep;17(3):187. No abstract available.

36.

Trends on epidemiological, virological, and clinical features among newly diagnosed HIV-1 persons in Northwest Spain over the last 10 years.

Pernas B, Mena A, Cañizares A, Grandal M, Castro-Iglesias A, Pértega S, Pedreira JD, Poveda E.

J Med Virol. 2015 Aug;87(8):1319-26. doi: 10.1002/jmv.24185. Epub 2015 Mar 16.

PMID:
25777786
37.

HIV tropism shift: new paradigm on cell therapy strategies for HIV cure.

Poveda E.

AIDS Rev. 2015 Jan-Mar;17(1):65. No abstract available.

PMID:
25608470
38.

Molecular characterization of HIV-1 infection in Northwest Spain (2009-2013): Investigation of the subtype F outbreak.

Paraskevis D, Kostaki E, Beloukas A, Cañizares A, Aguilera A, Rodríguez J, Grandal M, Pernas B, Castro-Iglesias A, Mena Á, Pedreira JD, Poveda E.

Infect Genet Evol. 2015 Mar;30:96-101. doi: 10.1016/j.meegid.2014.12.012. Epub 2014 Dec 16.

PMID:
25527396
39.

Seroprevalence of HCV and HIV infections by year of birth in Spain: impact of US CDC and USPSTF recommendations for HCV and HIV testing.

Mena A, Moldes L, Meijide H, Cañizares A, Castro-Iglesias A, Delgado M, Pértega S, Pedreira J, Bou G, Poveda E.

PLoS One. 2014 Dec 1;9(12):e113062. doi: 10.1371/journal.pone.0113062. eCollection 2014.

40.

Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study.

Garcia F, Poveda E, Pérez-Elías MJ, Quero JH, Ribas MA, Martínez-Madrid OJ, Flores J, Crespo M, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestarán A, Paredes R.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19520. doi: 10.7448/IAS.17.4.19520. eCollection 2014.

41.

Ingenol derivates promising for HIV eradication.

Poveda E.

AIDS Rev. 2014 Oct-Dec;16(4):246.

PMID:
25373349
42.

Highlights from CROI 2014 on experimental HIV drugs.

Poveda E, Pedreira JD.

AIDS Rev. 2014 Apr-Jun;16(2):118. No abstract available.

PMID:
24984767
43.

Update on hepatitis C virus resistance to direct-acting antiviral agents.

Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E.

Antiviral Res. 2014 Aug;108:181-91. doi: 10.1016/j.antiviral.2014.05.015. Epub 2014 Jun 6. Review. Erratum in: Antiviral Res. 2014 Nov;111:154.

PMID:
24911972
44.

High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment response.

Pernas B, Grandal M, Mena A, Castro-Iglesias A, Cañizares A, Wyles DL, López-Calvo S, Pértega S, Rodríguez-Osorio I, Pedreira JD, Poveda E.

AIDS. 2014 Jul 31;28(12):1837-40. doi: 10.1097/QAD.0000000000000326.

PMID:
24871456
45.

HIV-2 viral tropism influences CD4+ T cell count regardless of viral load.

Treviño A, Soriano V, Poveda E, Parra P, Cabezas T, Caballero E, Roc L, Rodríguez C, Eiros JM, Lopez M, De Mendoza C; HIV-2 Spanish Study Group.

J Antimicrob Chemother. 2014 Aug;69(8):2191-4. doi: 10.1093/jac/dku119. Epub 2014 Apr 30.

PMID:
24788659
46.

Multi-step inhibition against HIV lifecycle-underlying the "magic" of protease inhibitors.

Poveda E.

AIDS Rev. 2014 Jan-Mar;16(1):52. No abstract available.

PMID:
24589971
47.

Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers.

Mena Á, Pedreira JD, Castro Á, López S, Vázquez P, Poveda E.

J Gastroenterol Hepatol. 2014 Jan;29(1):173-8. doi: 10.1111/jgh.12432.

PMID:
24219115
48.

[Telaprevir resistance].

Poveda E, García F.

Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:26-32. doi: 10.1016/S0213-005X(13)70121-6. Review. Spanish.

PMID:
24063900
49.

Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy.

Barreiro P, Labarga P, Fernández-Montero JV, Poveda E, de Mendoza C, Sánchez C, Vispo E, Soriano V.

J Clin Virol. 2013 Oct;58(2):391-5. doi: 10.1016/j.jcv.2013.06.031. Epub 2013 Jul 30.

PMID:
23910933
50.

Hepatitis B in HIV-infected patients.

Soriano V, Poveda E, Vispo E, Barreiro P.

Clin Liver Dis. 2013 Aug;17(3):489-501. doi: 10.1016/j.cld.2013.05.008. Epub 2013 Jul 8. Review.

PMID:
23905818

Supplemental Content

Loading ...
Support Center